Researcher brief comment: The company is mainly engaged in innovative research, development, production and sales of biomedicine, and is a biomedical innovation enterprise with intellectual property as the core. The company continues to launch new technologies and products in the fields of genetically engineered drugs, photodynamic drugs, and nanopharmaceuticals, etc., forming a clear competitive advantage, and it is expected that new drugs will be launched on the market one after another in the future. The company officially switched from GEM to Main Board trading at 9 o'clock on December 16, 2013, and the code was changed from 8231.HK to 1349.HK. We believe this is an important milestone in the company's development. The company hopes to become a benchmark enterprise in the photopower field and maintain a good growth trend in the future. Investors are advised to keep a close eye on it.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Trump made a huge profit of 50 billion dollars; have you ever seen a U.S. president "issue currency"?
Weekend reading | After 5 years, Apple is finally going to give the iPhone a "facelift."
The central bank and the China Securities Regulatory Commission jointly held a seminar on Share Buyback and Shareholding re-loans, further leveraging policy tools to stabilize the Capital Markets.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
复旦张江(1349.HK)调研纪要
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report